Antiresorptive therapies in oncology and their effects on cancer progression

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 776-786

  Bundred, Nigel ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adjuvant therapy; Antiresorptive therapy; Bisphosphonates; Bone; Breast cancer; Denosumab; Endocrine therapy; Safety; Zoledronic acid

Indexed keywords

AGENTS AFFECTING METABOLISM; ALENDRONIC ACID; ANASTROZOLE; ANTIRESORPTIVE AGENT; CLODRONIC ACID; DENOSUMAB; GOSERELIN; IBANDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FRACTURE; HUMAN; INFECTION; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SOLID TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; NEOPLASM METASTASIS; NEOPLASMS; RANK LIGAND;

EID: 84861701380     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.002     Document Type: Review

References (151)

1. Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26:5465-5476.
2. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 2006, 15(Suppl. 1):S30-S40.
3. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
4. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
5. Powles T.J., McCloskey E., Paterson A.H., et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998, 90:704-708.
6. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006, 33(Suppl. 7):S13-S17.
7. Bruder J.M., Ma J.Z., Wing N., Basler J., Katselnik D. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 2006, 9:431-437.
8. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352.
9. Hadji P., Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 2007, 34(Suppl. 4):S4-S10.
10. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl. 1):S3-S18.
11. Hines S.L., Mincey B., Dentchev T., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609.
12. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010.
13. van Londen G.J., Perera S., Vujevich K.T., Sereika S.M., Bhattacharya R., Greenspan S.L. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial. Bone 2010, 46:655-659.
14. Swenson K.K., Nissen M.J., Anderson E., Shapiro A., Schousboe J., Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009, 7:101-107.
15. Hatoum H.T., Lin S.J., Guo A., Lipton A., Smith M.R. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011, 27:55-62.
16. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
17. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
18. Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194.
19. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
20. Smith M.R., Saad F., Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009, 182:2670-2675.
21. Ellis G.K., Bone H.G., Chlebowski R., et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009, 118:81-87.
22. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
23. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., Aapro M. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007, 43:852-858.
24. Saad F., Perrotte P., Benard F., McCormack M., Karakiewicz P.I. Bone health in men with prostate cancer: diagnostic and therapeutic considerations. Can J Urol 2005, 12(Suppl. 2):9-15.
25. Prolia [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2010.
26. Prolia (denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc. 2011. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf.
27. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80(Suppl.):1588-1594.
28. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
29. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
30. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
31. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
32. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
33. Xgeva (denosumab) injection [package insert]. Thousand Oaks, CA: Amgen Inc.; 2010.
34. Amgen Inc. Xgeva (denosumab) granted marketing authorization in the European Union [press release 2011]. 2011 [accessed 27.07.11]. http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1585714.
35. Coleman R.E. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?. Eur J Cancer 2009, 45:1909-1915.
36. Coleman R.E., Guise T.A., Lipton A., et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008, 14:6387-6395.
37. Coleman R.E., Winter M.C., Cameron D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
38. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
39. Avilés A., Nambo M.J., Neri N., Castaneda C., Cleto S., Huerta-Guzmán J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
40. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
41. Coleman R., Marshall H., Cameron D., et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405.
42. Gnant M., Mlineritsch B., Stoeger H., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641.
43. Cariati M., Purushotham A.D. Stem cells and breast cancer. Histopathology 2008, 52:99-107.
44. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48:37-43.
45. Islam A., Glomski C., Henderson E.S. Bone lining (endosteal) cells and hematopoiesis: a light microscopic study of normal and pathologic human bone marrow in plastic-embedded sections. Anat Rec 1990, 227:300-306.
46. Shiozawa Y., Havens A.M., Pienta K.J., Taichman R.S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950.
47. Safina A., Ren M.Q., Vandette E., Bakin A.V. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2008, 27:1198-1207.
48. Wels J., Kaplan R.N., Rafii S., Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008, 22:559-574.
49. Aft R., Naughton M., Trinkaus K., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
50. Greenberg S., Park J.W., Melisko M.E., et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results. J Clin Oncol 2010, 28(Suppl.):114s. [abstract 1002].
51. Raghu H., Sodadasu P.K., Malla R.R., Gondi C.S., Estes N., Rao J.S. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10:647.
52. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
53. Bhoopathi P., Chetty C., Kunigal S., Vanamala S.K., Rao J.S., Lakka S.S. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 2008, 283:1545-1552.
54. Shin S.Y., Nam J.S., Lim Y., Lee Y.H. TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 2010, 285:30731-30740.
55. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
56. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
57. Franco G.C., Kajiya M., Nakanishi T., et al. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Exp Cell Res 2011.
58. Lipton A., Chapman J.A., Demers L., et al. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol 2011, 29:3605-3610.
59. Smith M.R., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2011, 379:39-46.
60. Bendre M.S., Margulies A.G., Walser B., et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005, 65:11001-11009.
61. Green J., Lipton A. Anticancer properties of zoledronic acid. Cancer Invest 2010, 28:944-957.
62. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010, 126:522-532.
63. Santini D., Vincenzi B., Galluzzo S., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482-4486.
64. Santini D., Vincenzi B., Hannon R.A., et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 2006, 15:1351-1357.
65. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
66. Sato K., Kimura S., Yuasa T., Wada H., Maekawa T. Cancer immunotherapy: cytotoxic activity of {gamma}{delta} T-cells expanded ex vivo by the third generation bisphosphonate zoledronate. Blood (ASH Annual Meeting Abstracts) 2004, 104. [abstract 1347].
67. Dieli F., Vermijlen D., Fulfaro F., et al. Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007, 67:7450-7457.
68. Allan A.L., Vantyghem S.A., Tuck A.B., Chambers A.F. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006, 26:87-98.
69. Fromigue O., Lagneaux L., Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000, 15:2211-2221.
70. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82:1459-1468.
71. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134.
72. Senaratne S.G., Mansi J.L., Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002, 86:1479-1486.
73. Senaratne S.G., Colston K.W. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002, 4:18-23.
74. Monkkonen H., Kuokkanen J., Holen I., et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19:391-399.
75. Verdijk R., Franke H.R., Wolbers F., Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007, 246:308-312.
76. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
77. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
78. Bezzi M., Hasmim M., Bieler G., Dormond O., Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003, 278:43603-43614.
79. Muller S., Migianu E., Lecouvey M., Kraemer M., Oudar O. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res 2005, 25:2655-2660.
80. Montague R., Hart C.A., George N.J., Ramani V.A., Brown M.D., Clarke N.W. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol 2004, 46:389-401. [discussion follows].
81. Guo Y., Tiedemann K., Khalil J.A., Russo C., Siegel P.M., Komarova S.V. Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 2008, 43:386-393.
82. Thomas R.J., Guise T.A., Yin J.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
83. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
84. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
85. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
86. Hanada R., Hanada T., Penninger J.M. Physiology and pathophysiology of the RANKL/RANK system. Biol Chem 2010, 391:1365-1370.
87. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
88. Chaisson M.L., Branstetter D.G., Derry J.M., et al. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 2004, 279:54841-54848.
89. Martin T.J., Gillespie M.T. Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone. Trends Endocrinol Metab 2001, 12:2-4.
90. Schramek D., Leibbrandt A., Sigl V., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
91. Fernandez-Valdivia R., Mukherjee A., Ying Y., et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 2009, 328:127-139.
92. Beleut M., Rajaram R.D., Caikovski M., et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010, 107:2989-2994.
93. Kim N.S., Kim H.J., Koo B.K., et al. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006, 26:1002-1013.
94. Fata J.E., Kong Y.Y., Li J., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
95. Curtis J.R. The role of 7, 12 DMBA and three hormones in 7, 12 DMBA-induced rat mammary cancer: three hypotheses. Med Hypotheses 1982, 9:489-507.
96. Coscia M., Quaglino E., Iezzi M., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815.
97. Tan W., Zhang W., Strasner A., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
98. Gonzalez-Suarez E., Jacob A.P., Jones J., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
99. Gonzalez-Suarez E., Branstetter D., Armstrong A., Dinh H., Blumberg H., Dougall W.C. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 2007, 27:1442-1454.
100. Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29:3366-3373.
101. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
102. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
103. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8:R13. [ISRCTN83688026].
104. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
105. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
106. Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
107. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577-3581.
108. Newcomb P.A., Trentham-Dietz A., Hampton J.M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799-802.
109. Chlebowski R.T., Chen Z., Cauley J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590.
110. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011 [abstract S2-3].
111. Möbus V, Diel IJ, Harbeck N, et al. GAIN (German Adjuvant Intergroup Node Positive) study: a phase-III multicenter trial to compare dose dense, dose intense ETC. (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10; 2011 [abstract S2-4].
112. de Boer R, Bundred N, Eidtmann H, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at: 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12; 2010 [abstract P5-11-01].
113. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
114. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
115. Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13; 2009 [abstract 4082].
116. Zarogoulidis K., Boutsikou E., Zarogoulidis P., et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125:1705-1709.
117. Zaghloul M.S., Boutrus R., El-Hossieny H., Kader Y.A., El-Attar I., Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010, 15:382-389.
118. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22:195-201.
119. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancer [oral]. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10; 2011 [abstract S1-2].
120. Bidard F.C., Kirova Y.M., Vincent-Salomon A., et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 2009, 20:1836-1841.
121. Lin A.Y., Park J.W., Scott J., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(Suppl.):20s. [abstract 559].
122. Solomayer E., Gebauer G., Hirnle P., et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(Suppl. 2):170s-171s. [abstract 2048].
123. Rack B., Juckstock J., Genss E.-M., et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
124. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
125. Norton L., Massague J. Is cancer a disease of self-seeding?. Nat Med 2006, 12:875-878.
126. Camara O., Kavallaris A., Noschel H., Rengsberger M., Jorke C., Pachmann K. Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol 2006, 4:67.
127. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?. Breast Cancer Res Treat 2010, 122:627-636.
128. Katamura Y., Aikata H., Hashimoto Y., et al. Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. Hepatol Res 2010, 40:1195-1203.
129. Russell H.V., Groshen S.G., Ara T., et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2010, [Epub ahead of print].
130. Santini D., Martini F., Fratto M.E., et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38.
131. Naoe M., Ogawa Y., Takeshita K., et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 2010, 18:493-501.
132. Meraviglia S., Eberl M., Vermijlen D., et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010, 161:290-297.
133. Kondo M., Sakuta K., Noguchi A., et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008, 10:842-856.
134. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 2008, 25:346-349.
135. Ferretti G., Fabi A., Carlini P., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005, 69:35-43.
136. Vincenzi B., Santini D., Dicuonzo G., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005, 25:144-151.
137. Winter MC, Syddall SP, Cross SS, et al. ANZAC: a randomised neoadjuvant biomarker study investigating the anti-tumour activity of the addition of zoledronic acid to chemotherapy in breast cancer. Presented at: the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12; 2010 [abstract P1-11-01].
138. Body J-J, Cook RJ, Costa L, et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at: IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, October 28-31; 2009 [poster 71].
139. Hirsh V., Major P.P., Lipton A., et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236.
140. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
141. Ferrari-Lacraz S., Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporos Int 2011, 22:435-446.
142. Romas E., Gillespie M.T. Inflammation-induced bone loss: can it be prevented?. Rheum Dis Clin North Am 2006, 32:759-773.
143. US Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs. Denosumab. 2011 [accessed 14.03.11]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM176595.pdf.
144. Watts N.B., Roux C., Modlin J.F., et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos Int 2012, 23:327-337.
145. Toulis K.A., Anastasilakis A.D. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010, 21:1963-1964.
146. von Keyserlingk C., Hopkins R., Anastasilakis A., et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 2011, 41:178-186.
147. Fizazi K., Carducci M.A., Smith M.R., et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010, 28(Suppl.):343s. [abstract LBA4507].
148. Cardinale D., Colombo A., Torrisi R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28:3910-3916.
149. Goss PE, Barrios CH, Bell R, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). Poster presented at: 2011 Annual ASCO Meeting, Chicago, IL, June 3-7; 2011 [abstract TPS152].
150. Bundred N.J., Prasad R., Morris J., et al. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?. Breast Cancer Res Treat 2011, [Epub ahead of print].
151. Cancer Research UK. Breast cancer statistics-key factors. 2011 [accessed 29.04.11]. http://info.cancerresearchuk.org/cancerstats/types/breast/.